Opill Proposal Makes ACNU Sense, Stakeholders Comment On US 'Additional Conditions' Proposal
As pharma marketing and Rx-to-OTC switch experts told HBW Insight, health care industry stakeholders submitting comments to the FDA connect Opill NDA to FDA’s consideration of an ACNU pathway.
You may also be interested in...
“Who would have said that, looking forward two or three years ago, we would be where we are now?” says FDA OTC office director Theresa Michele. Monograph reform and introducing “additional conditions for nonprescription use” options for NDA OTCs each is a “real gamechanger.”
Periodic summaries FDA is considering are “most effective method to track and report relevant concerns,” but “failure” as outlined in proposed rule is too broad, says CHPA. Digital care delivery firm Amwell says FDA should ask ACNU OTC marketers for some individual adverse event reports in addition to summaries.
HRA didn't have time to incorporate into its switch NDA instructions stated in proposed ACNU rule published in June, but the firm, which worked with Ibis Reproductive Health on proposal, had time to plumb a draft guidance FDA published in 2018 on novel switches.